The beginning of the end for MRSA?

A revolutionary new device with the technology to kill most pathogenic airborne and surface bacteria and viruses has been launched this week.

The new technology behind Cirrus 3 can be used in hospitals, doctor’s waiting rooms, aeroplanes, public transport, hotel lobbies, casinos and cruise ships, having a huge positive impact on the public’s health.

Alan Mole, Director of Tri-Air Developments Ltd who invented the technology said, “The Cirrus 3 could dramatically affect the way viruses and bacteria are transmitted around the world and ultimately reduce global health threats. After 20 years of work it’s a momentous day to finally see the technology available commercially.”

The Cirrus 3 combines three existing and established decontamination technologies to create an invisible defence cloud that kills germs before they can spread from person to person.

The unique technology contained in the Cirrus 3 manufactures a continual stream of hydroxyl radicals that are found in abundance in the natural environment and destroy any harmful bacteria in the outside air. To recreate fresh air indoors it combines UV light with extremely low levels of ozone and mixes it with volatile hydrocarbons (given off by plants). It is all perfectly safe and leaves the air pure, clean, fresh and germ free.

Since 2006 Tri-Air Developments have conducted efficacy testing of the technology, with results including a kill of 99.9999% within minutes of the airborne test virus MS2-Phage, and a kill of between 99% and 99.99% of different surface based MRSA over a 48hr test period.

Commenting on the benefits of Cirrus3, Roy Carter, CEO of BA Holdings, the company behind the device says: “With health threats such as the recent Swine Flu scare predicted to cost the UK economy over £72 billion**, there is increasing concern about the transmission of infection in places where people are in close contact. This is where the Cirrus3 comes in – in a few simple steps, the air is literally wiped clean.”

For more information visit cirrus3.com.

** Figures published in the British Medical Journal compiled by the London School of Economics, London School of Hygiene and Tropical Medicine and Edinburgh University.